Skip to main content

Table 1 Associations of serum glutamine level with clinicopathological characteristics of CRC patients

From: Glutamine deficiency promotes recurrence and metastasis in colorectal cancer through enhancing epithelial–mesenchymal transition

Variable

No. of cases

Glutamine (μM)

P values

Mean

SD

Age (year)

0.147

 ≥ 65

56

593.52

418.88

 

 < 65

65

493.14

337.12

 

Sex

0.860

 Male

73

534.65

344.40

 

 Female

48

547.11

429.81

 

BMI

0.278

 < 18.5

12

383.02

343.87

 

 18.5–23.9

64

577.94

394.39

 

 24–26.9

28

480.44

378.68

 

 ≥ 27

17

603.22

326.02

 

Tumor size (cm)

0.503

 ≥ 5

68

519.12

373.75

 

 < 5

53

565.87

387.38

 

Tumor location

0.161

 Colon

61

491.58

349.99

 

 Rectum

60

588.41

403.25

 

Tumor differentiation

0.563

 Well and moderate

93

550.60

376.72

 

 Poor

28

503.05

390.74

 

Depth of invasion

0.007*

 Tis–T2

23

601.45

360.58

 

 T3

82

575.39

387.13

 

 T4

16

267.23

237.72

 

Lymph node metastasis

0.037*

 Yes

59

466.17

409.97

 

 No

62

609.47

335.31

 

Venous permeation

0.161

 Yes

55

486.62

416.73

 

 No

66

583.75

341.18

 

Perineural invasion

0.94

 Yes

27

534.73

362.30

 

 No

94

540.99

385.40

 

CEA

 High

21

435.13

309.45

0.017*

 Normal

60

636.65

329.39

 

Survival status

0.259

 Death

42

486.07

427.31

 

 Survival

79

568.05

350.03

 

Metastasis/recurrence

0.008*

 Yes

49

430.11

372.35

 

 No

72

614.11

367.43

 
  1. BMI body mass index, CEA carcinoembryonic antigen
  2. *Statistically significant